Successful Crizotinib-targeted Therapy of Pediatric Unresectable ERC1::ALK Fusion Sarcoma

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic lymphoma kinase (ALK)-fusion sarcomas represent a rare subset of sarcomas.
• These tumors are associated with the tyrosine kinase RAS::MAPK pathway.
• Emerging research suggests these fusions are theoretically targetable.

Purpose of the Study:

• To describe the clinicopathologic features and treatment outcomes of a novel ALK-fusion sarcoma.
• To evaluate the efficacy of crizotinib in treating this rare sarcoma subtype.
• To assess the long-term response to ALK-targeted therapy.

Main Methods:

• Case report of a 15-month-old male with a right-hand sarcoma.
• Identification of a novel ELKS/RAB6-interacting/CAST family member 1-unaligned ALK fusion.
• Treatment with oral monotherapy crizotinib, an ALK tyrosine kinase inhibitor.

Main Results:

• Complete radiographic and clinical resolution was achieved within 10 months of crizotinib treatment.
• A sustained response was observed for over 12 months after elective discontinuation of the drug.
• The treatment demonstrated successful management of an unresectable, novel ALK-fusion sarcoma.

Conclusions:

• Crizotinib is an effective oral monotherapy for novel ALK-fusion sarcomas.
• Targeted therapy with ALK inhibitors can lead to complete resolution in pediatric patients.
• This case highlights the potential of ALK-targeted therapy for rare fusion-driven sarcomas.